The credit rating agency Fitch Ratings has revised Grifols' rating upwards, raising its long-term issuer rating to B+, reflecting a lower probability of default by the pharmaceutical company, which has had a high level of debt for years.
The credit rating agency Fitch Ratings has revised Grifols' rating upwards, raising its long-term issuer rating to B+, reflecting a lower probability of default by the pharmaceutical company, which has had a high level of debt for years.